Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression. Two ETS transcription factors, ERG and ETV1 , were identified as outliers in prostate cancer. We identified recurrent gene fusions of the 5′ untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1 . Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high expression levels of ERG and PEA3 subfamily members in a subset of prostate tumors led to the discovery of common chromosomal rearrangements associated with this human cancer (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Chromosomal rearrangements that result in the overexpression of members of the PEA3 subfamily (ETV1, ETV4, or ETV5) are found less frequently (36, 170, 171).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Rearrangements of ETS loci are a hallmark of prostate cancer with ~50% of tumors showing alterations at an ETS gene locus (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Self-citationChromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Research works printed but not linked: 5
- I. S. Jeon et al., Oncogene10, 1229 (1995).
- B. Lin et al., Cancer Res.59, 4180 (1999).
- D. E. Afar et al., Cancer Res.61, 1686 (2001).
- S. M. Dhanasekaran et al., FASEB J.19, 243 (2005).
- J. B. Welsh et al., Cancer Res.61, 5974 (2001).
Cited by
Items 601–700 of 1,014
Naderi, A., Teschendorff, A. E., Beigel, J., Cariati, M., Ellis, I. O., Brenton, J. D., & Caldas, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4394 · Cited by 114
Fine, S. W., Gopalan, A., Leversha, M. A., Al‐Ahmadie, H. A., Tickoo, S. K., Zhou, Q. C., Satagopan, J. M., Scardino, P. T., Gerald, W. L., & Reuter, V. E. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.120 · Cited by 103
Androgen-Induced TMPRSS2:ERG Fusion in Nonmalignant Prostate Epithelial Cells
Bastus, N. C., Boyd, L. K., Mao, X., Stankiewicz, E., Kudahetti, S. C., Oliver, R. T. D., Berney, D. M., & Lu, Y. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1638 · Cited by 105
A Short History of Chromosome Rearrangements and Gene Fusions in Cancer
Mitelman, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-19983-2_1 · Cited by 103
Abiraterone acetate in the treatment of prostate cancer
Thakur, A., Roy, A., Ghosh, A., Chhabra, M., & Banerjee, S. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.067 · Cited by 112
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
Ferguson, S. D., Zhou, S., Huse, J. T., de Groot, J., Xiu, J., Subramaniam, D. S., Mehta, S. V., Gatalica, Z., Swensen, J. J., Sanai, N., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly022 · Cited by 106
Han, B., Suleman, K., Wang, L., Siddiqui, J., Sercia, L., Magi‐Galluzzi, C., Palanisamy, N., Chinnaiyan, A. M., Zhou, M., & Shah, R. B. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181d6827b · Cited by 108
Self-citationIdentifying fusion transcripts using next generation sequencing
Kumar, S., Razzaq, S. K., Vo, A. D., Gautam, M., & Li, H. (2016) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1382 · Cited by 132
Fusion genes in solid tumors: an emerging target for cancer diagnosis and treatment
Parker, B. C., & Zhang, W. (2013) · Chinese Journal of Cancer · doi:10.5732/cjc.013.10178 · Cited by 94
Truncated ETV1, Fused to Novel Tissue-Specific Genes, and Full-Length ETV1 in Prostate Cancer
Hermans, K. G., van der Korput, H. A., van Marion, R., van de Wijngaart, D. J., der Made, A. Z., Dits, N. F. J., Boormans, J. L., van der Kwast, T., van Dekken, H., Bangma, C. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5930 · Cited by 117
“At low frequency, fusions of TMPRSS2 to ETV1, ETV4, and ETV5, which map on different chromosomes, have been described (5, 7, 8 , 10).”
BackgroundBaldus, C. D., Mrózek, K., Marcucci, G., & Bloomfield, C. D. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06566.x · Cited by 102
The ageing male reproductive tract
Sampson, N., Untergasser, G., Plas, E., & Berger, P. (2007) · The Journal of Pathology · doi:10.1002/path.2077 · Cited by 120
Gu, X., Zerbini, L. F., Otu, H. H., Bhasin, M., Yang, Q., Joseph, M. G., Grall, F. T., Onatunde, T., Correa, R. G., & Libermann, T. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3689 · Cited by 112
Han, W., Gao, S., Barrett, D. A., Ahmed, M., Han, D. G., Macoska, J. A., He, H. H., & Cai, C. (2017) · Oncogene · doi:10.1038/onc.2017.385 · Cited by 108
Single Enantiomer of YK-4-279 Demonstrates Specificity in Targeting the Oncogene EWS-FLI1
Barber-Rotenberg, J. S., Selvanathan, S. P., Kong, Y., Erkizan, H. V., Snyder, T. M., Hong, S. P., Kobs, C. L., South, N. L., Summer, S., Monroe, P. J., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.454 · Cited by 103
Cancer outlier differential gene expression detection
Wu, B. (2006) · Biostatistics · doi:10.1093/biostatistics/kxl029 · Cited by 109
“Biostatistics (2007), 8, 3, pp. 566–575 doi:10.1093/biostatistics/kxl029 Advance Access publication on October 4, 2006 Cancer outlier differential gene expression detection”
BackgroundInfluentialThe lysine specific demethylase‐1 (LSD1/KDM1A) regulates VEGF‐A expression in prostate cancer
Kashyap, V., Ahmad, S., Nilsson, E. M., Helczynski, L., Kenna, S., Persson, J. L., Gudas, L. J., & Mongan, N. P. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.01.003 · Cited by 111
“Furthermore, we show that LSD1 positively regulates the Tmprss2 locus, which is implicated in recurrent gene fusions in PCa (Tomlins et al., 2005; Yu et al., 2010).”
BackgroundRecurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma
Li, Y., Liu, Z., Lin, Z.-R., Xu, L.-H., Zhong, Q., & Zeng, M. (2014) · Cancer Biology & Therapy · doi:10.4161/15384047.2014.961874 · Cited by 100
Prostate Cancer Stem Cells: Do They Have a Basal or Luminal Phenotype?
Maitland, N. J., Frame, F. M., Polson, E. S., Lewis, J. L., & Collins, A. T. (2011) · Hormones and Cancer · doi:10.1007/s12672-010-0058-y · Cited by 116
Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS
Dey, P., Barros, R. P. A., Warner, M. N., Ström, A., & Gustafsson, J.-Α. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0150 · Cited by 124
“Expression of this fusion gene leads to castration resistant prostate cancer (Tomlins et al. 2005, Yu et al. 2010).”
BackgroundZhu, H., Uusküla-Reimand, L., Isaev, K., Wadi, L., Alizada, A., Shuai, S., Huang, V., Aduluso-Nwaobasi, D., Paczkowska, M., Abd-Rabbo, D., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.027 · Cited by 101
Prostate-specific antigen and other serum and urine markers in prostate cancer
Stephan, C., Ralla, B., & Jung, K. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.04.001 · Cited by 114
NTRK1 Fusion in Glioblastoma Multiforme
Kim, J., Lee, Y., Cho, H., Lee, Y., An, J., Cho, G.-H., Ko, Y. H., Joo, K. M., & Nam, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091940 · Cited by 101
Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer
Hu, Y., Dobi, A., Sreenath, T., Cook, C., Tadase, A. Y., Ravindranath, L., Cullen, J. C., Furusato, B., Chen, Y., Thangapazham, R. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0531 · Cited by 99
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer
Wang, X., Qiao, Y., Asangani, I. A., Ateeq, B., Poliakov, A., Cieslik, M. P., Pitchiaya, S., Chakravarthi, B. V. S. K., Cao, X., Jing, X., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.017 · Cited by 101
Self-citationAndrogen deprivation–induced NCoA2 promotes metastatic and castration-resistant prostate cancer
Qin, J., Lee, H.-J., Wu, S., Lin, S., Lanz, R. B., Creighton, C. J., DeMayo, F. J., Tsai, S. Y., & Tsai, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci76412 · Cited by 100
Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma
Han, B., Mehra, R., Suleman, K., Tomlins, S. A., Wang, L., Singhal, N., Linetzky, K. A., Palanisamy, N., Zhou, M., Chinnaiyan, A. M., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.79 · Cited by 102
Self-citationSequencing Structural Variants in Cancer for Precision Therapeutics
Macintyre, G., Ylstra, B., & Brenton, J. D. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.07.002 · Cited by 110
Gaudreau, P.-O., Stagg, J., Soulières, D., & Saad, F. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s31802 · Cited by 115
The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
Eisermann, K., & Fraizer, G. C. (2017) · Cancers · doi:10.3390/cancers9040032 · Cited by 103
Vainio, P., Lehtinen, L., Mirtti, T., Hilvo, M., Seppänen-Laakso, T., Virtanen, J., Sankila, A., Nordling, S., Lundin, J., Rannikko, A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.397 · Cited by 96
Longoni, N., Sarti, M., Albino, D., Civenni, G., Malek, A. V., Ortelli, E., Pinton, S., Grand, M. M., Ostano, P., D’Ambrosio, G., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4537 · Cited by 98
Asp, J., Persson, F., Kost‐Alimova, M., & Stenman, G. (2006) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20346 · Cited by 100
Androgen regulation of prostate cancer: Where are we now?
Corona, G., Baldi, E., & Maggi, M. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03347072 · Cited by 110
Hussain, M., Carducci, M. A., Slovin, S. F., Cetnar, J. P., Qian, J. X., McKeegan, E. M., Refici-Buhr, M., Chyla, B., Shepherd, S. P., Giranda, V. L., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0099-0 · Cited by 101
Prostate cancer in East Asia: evolving trend over the last decade
Ye, D., Zhu, Y., Wang, H., & Qu, Y. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.132780 · Cited by 101
Guo, W., Lasky, J. L., & Wu, H. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000203592.04530.06 · Cited by 120
Knight, J. F., Shepherd, C. J., Rizzo, S., Brewer, D. S., Jhavar, S. G., Dodson, A. R., Cooper, C. S., Eeles, R. A., Falconer, A., Kovács, G., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604774 · Cited by 97
ERG Is a Critical Regulator of Wnt/LEF1 Signaling in Prostate Cancer
Wu, L., Zhao, J. C., Kim, J., Jin, H., Wang, C.-Y., & Yu, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0882 · Cited by 102
Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes
McBride, D. J., Etemadmoghadam, D., Cooke, S. L., Alsop, K., George, J., Butler, A., Cho, J., Galappaththige, D., Greenman, C., Howarth, K. D., et al. (2012) · The Journal of Pathology · doi:10.1002/path.4042 · Cited by 97
Recent progress and perspectives on prostate cancer biomarkers
Hatakeyama, S., Yoneyama, T., Tobisawa, Y., & Οhyama, C. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-1049-y · Cited by 109
Unraveling the Genetics of Cancer: Genome Sequencing and Beyond
Wong, K. M., Hudson, T. J., & McPherson, J. D. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141532 · Cited by 108
ESR1 alterations and metastasis in estrogen receptor positive breast cancer
Lei, J. T., Gou, X., Şeker, S., & Ellis, M. J. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2019.12 · Cited by 117
Fibroblast growth factor receptor fusions in cancer: opportunities and challenges
Chen, L., Zhang, Y., Yin, L., Cai, B., Huang, P. C., Li, X., & Liang, G. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02156-6 · Cited by 96
Miyagi, Y., Sasaki, T., Fujinami, K., Sano, J., Senga, Y., Miura, T., Kameda, Y., Sakuma, Y., Nakamura, Y., Harada, M., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.149 · Cited by 96
Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Endocrinology · doi:10.1210/en.2013-1466 · Cited by 110
Epidemiology, Etiology, and Prevention of Prostate Cancer
Abouassaly, R., Thompson, I. M., Platz, E. A., & Klein, E. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6911-9.00095-5 · Cited by 108
Skerget, S., Penaherrera, D., Chari, A., Jagannath, S., Siegel, D. S., Vij, R., Orloff, G., Jakubowiak, A., Niesvizky, R., Liles, D., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01853-0 · Cited by 95
Cao, D., Ye, D., Zhang, H., Zhu, Y., Wang, Y., & Yao, X. (2010) · The Prostate · doi:10.1002/pros.21286 · Cited by 100
Stephan, C., Jung, K., Semjonow, A., Schulze‐Forster, K., Cammann, H., Hu, X., Meyer, H., Bögemann, M., Miller, K., & Friedersdorff, F. (2012) · Clinical Chemistry · doi:10.1373/clinchem.2012.195560 · Cited by 98
“PCA3 30 (16–60) [1–333] 51 (25–88) [7–231] 22.”
InfluentialTMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer
Reig, Ò., Marín‐Aguilera, M., Carrera, G., Jiménez, N., Paré, L., García‐Recio, S., Gaba, L., Pereira, M. V., Fernández, P. L., Prat, A., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.034 · Cited by 103
Smith, S. C., Buehler, D. G., Choi, E.-Y. K., McHugh, J. B., Rubin, B. P., Billings, S. D., Balzer, B. L., Thomas, D. G., Lucas, D. R., Goldblum, J. R., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.83 · Cited by 95
MicroRNA in prostate cancer: functional importance and potential as circulating biomarkers
Jackson, B. L., Grabowska, A. M., & Ratan, H. L. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-930 · Cited by 106
“Localised and metastatic Distinguishes low/intermediate/high risk localised disease in combination with MiR-21, MiR-145, MiR-221 [54]”
BackgroundValidation and clinical utility of prostate cancer biomarkers
Scher, H. I., Morris, M. J., Larson, S. M., & Heller, G. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.30 · Cited by 97
A chromatin structure‐based model accurately predicts DNA replication timing in human cells
Gindin, Y., Valenzuela, M. S., Aladjem, M. I., Meltzer, P. S., & Bilke, S. (2014) · Molecular Systems Biology · doi:10.1002/msb.134859 · Cited by 94
Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer
Ding, Y., Li, N., Dong, B., Guo, W., Wei, H., Chen, Q., Yuan, H., Han, Y., Chang, H., Kan, S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123557 · Cited by 97
Hawley, J. E., Obradović, A., Dallos, M. C., Lim, E. A., Runcie, K. D., Ager, C. R., McKiernan, J., Anderson, C. B., DeCastro, G. J., Weintraub, J. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.10.006 · Cited by 100
Twenty Years of PSA: From Prostate Antigen to Tumor Marker.
Angelis, G. D., Rittenhouse, H. G., Mikolajczyk, S. D., Shamel, L. B., & Semjonow, A. (2007) · Europe PMC (PubMed Central) · Cited by 94
Detection of pre-neoplastic and neoplastic prostate disease by MADI profiling of urine
M’Koma, A. E., Blum, D. L., Norris, J. L., Koyama, T., Billheimer, D. D., Motley, S. S., Ghiassi, M., Ferdowsi, N., Bhowmick, I., Chang, S. S., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.12.111 · Cited by 104
The emerging role of speckle-type POZ protein (SPOP) in cancer development
Mani, R. S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.07.009 · Cited by 94
Demystifying the secret mission of enhancers: linking distal regulatory elements to target genes
Yao, L., Berman, B. P., & Farnham, P. J. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1087961 · Cited by 93
Zhou, C. K., Young, D., Yeboah, E. D., Coburn, S. B., Tettey, Y., Biritwum, R. B., Adjei, A. A., Tay, E., Niwa, S., Truelove, A. L., et al. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kwx235 · Cited by 97
Hermans, K. G., Boormans, J. L., Tandefelt, D. G., van Leenders, G. J. L. H., Jenster, G. W., Verhagen, P. C. M. S., & Trapman, J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1176 · Cited by 100
FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer
Paulo, P., Barros-Silva, J. D., Ribeiro, F. R., Ramalho‐Carvalho, J., Jerónimo, C., Henrique, R., Lind, G. E., Skotheim, R. I., Lothe, R. A., & Teixeira, M. R. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20948 · Cited by 103
“Rearrangement of TMPRSS2 with ERG has been recurrently found in around 50% of prostate adenocarcinomas (PCa) and 20% of precursor high-grade prostatic intraepithelial neoplasia (HGPIN) lesions (Tomlins et al., 2005; Cerveira et al., 2006; Tomlins et al., 2009).”
BackgroundFang, Z., Soleymani, L., Pampalakis, G., Yoshimoto, M., Squire, J. A., Sargent, E. H., & Kelley, S. O. (2009) · ACS Nano · doi:10.1021/nn900733d · Cited by 93
Biomarkers for Prostate Cancer Detection
Parekh, D. J., Ankerst, D. P., Troyer, D. A., Srivastava, S., & Thompson, I. M. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.055 · Cited by 93
Qian, X., Ara, G., Mills, E., LaRochelle, W. J., Lichenstein, H. S., & Jeffers, M. (2007) · International Journal of Cancer · doi:10.1002/ijc.23243 · Cited by 97
Long, Q., Johnson, B. A., Osunkoya, A. O., Lai, Y., Zhou, W., Abramovitz, M., Xia, M., Bouzyk, M., Nam, R. K., Sugar, L., et al. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.03.008 · Cited by 97
Rahrmann, E. P., Collier, L. S., Knutson, T. P., Doyal, M. E., Kuslak, S. L., Green, L. E., Malinowski, R. L., Roethe, L., Akagi, K., Waknitz, M. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3901 · Cited by 106
Wang, J., Koo, K. M., Wee, E. J. H., Wang, Y., & Trau, M. (2017) · Nanoscale · doi:10.1039/c6nr09928a · Cited by 93
FGF23 promotes prostate cancer progression
Feng, S., Wang, J., Zhang, Y., Creighton, C. J., & Ittmann, M. (2015) · Oncotarget · doi:10.18632/oncotarget.4174 · Cited by 92
Tomlins, S. A., Palanisamy, N., Siddiqui, J., Chinnaiyan, A. M., & Kunju, L. P. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0424-oa · Cited by 92
Self-citationGuzmán‐Ramírez, N., Völler, M., Wetterwald, A., Germann, M., Cross, N. A., Rentsch, C. A., Schalken, J. A., Thalmann, G. N., & Cecchini, M. G. (2009) · The Prostate · doi:10.1002/pros.21018 · Cited by 92
Salivary exosomes as potential biomarkers in cancer
Nair, S., Tang, K. D., Kenny, L., & Punyadeera, C. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.07.001 · Cited by 97
Biomarkers of Aggressive Prostate Cancer at Diagnosis
Boehm, B. E., York, M. E., Petrovics, G., Kohaar, I., & Chesnut, G. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032185 · Cited by 92
Tian, T. V., Tomavo, N., Huot, L., Flourens, A., Bonnelye, E., Flajollet, S., Hot, D., Leroy, X., de Launoit, Y., & Duterque‐Coquillaud, M. (2013) · Oncogene · doi:10.1038/onc.2013.176 · Cited by 97
Böttcher, E., Freuer, C., Steinmetzer, T., Klenk, H., & Garten, W. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.03.029 · Cited by 92
ETS fusion genes in prostate cancer
Tandefelt, D. G., Boormans, J. L., Hermans, K. G., & Trapman, J. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0390 · Cited by 105
Patil, V. S., Pal, J., & Somasundaram, K. (2015) · Oncotarget · doi:10.18632/oncotarget.6171 · Cited by 95
Inflammation-Induced Oxidative Stress Mediates Gene Fusion Formation in Prostate Cancer
Mani, R. S., Amin, M. A., Li, X., Sundaram, S. K., Veeneman, B. A., Wang, L., Ghosh, A., Aslam, A. J., Ramanand, S. G., Rabquer, B. J., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.019 · Cited by 95
Self-citationERF mutations reveal a balance of ETS factors controlling prostate oncogenesis
The International SU2C/PCF Prostate Cancer Dream Team, Bose, R., Karthaus, W. R., Armenia, J., Abida, W., Iaquinta, P. J., Zhang, Z., Wongvipat, J., Wasmuth, E. V., Shah, N., et al. (2017) · Nature · doi:10.1038/nature22820 · Cited by 90
Clonal Progression of Prostate Cancers from Gleason Grade 3 to Grade 4
Sowalsky, A. G., Ye, H., Bubley, G. J., & Balk, S. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2799 · Cited by 91
Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer
Smolle, M. A., Bauernhofer, T., Pummer, K., Călin, G. A., & Pichler, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020473 · Cited by 97
High-resolution identification of balanced and complex chromosomal rearrangements by 4C technology
Simonis, M., Klous, P., Homminga, I., Galjaard, R. H., Rijkers, E., Grosveld, F. G., Meijerink, J. P. P., & de Laat, W. L. (2009) · Nature Methods · doi:10.1038/nmeth.1391 · Cited by 106
“Finally, candidate loci may represent genes that are aberrantly expressed without apparent variation in their DNA copy numbe”
BackgroundKlomp, J. A., Petillo, D., Niemi, N. M., Dykema, K. J., Chen, J., Yang, X. J., Sääf, A. M., Zickert, P., Aly, M., Bergerheim, U. S. R., et al. (2010) · BMC Medical Genomics · doi:10.1186/1755-8794-3-59 · Cited by 91
The molecular biology of prostate cancer: current understanding and clinical implications
Gandhi, J., Afridi, A., Vatsia, S. K., Joshi, G. A., Joshi, G. S., Kaplan, S. A., Smith, N. L., & Khan, S. A. (2017) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-017-0023-8 · Cited by 106
Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer
Yan, Y., & Huang, H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_14 · Cited by 98
TMPRSS2: Potential Biomarker for COVID‐19 Outcomes
Strope, J. D., Chau, C. H., & Figg, W. D. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1641 · Cited by 90
Yuan, L., Nikolova-Krstevski, V., Zhan, Y., Kondo, M., Bhasin, M., Varghese, L., Yano, K., Carman, C. V., Aird, W. C., & Oettgen, P. (2009) · Circulation Research · doi:10.1161/circresaha.108.190751 · Cited by 97
Katapadi, V. K., Nambiar, M., & Raghavan, S. C. (2012) · Genomics · doi:10.1016/j.ygeno.2012.05.008 · Cited by 91
Evaluation of Paired-End Sequencing Strategies for Detection of Genome Rearrangements in Cancer
Bashir, A., Volik, S. V., Collins, C. C., Bafna, V., & Raphael, B. J. (2008) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000051 · Cited by 105
Fusion genes and their discovery using high throughput sequencing
Annala, M., Parker, B. C., Zhang, W., & Nykter, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.011 · Cited by 96
Sagredo, A. I., Sagredo, E. A., Cappelli, C., Pablo Báez, B., Andaur, R., Blanco, C., Tapia, J. C., Echeverría, C., Cerda, O., Stutzin, A., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12100 · Cited by 96
Advancing Precision Medicine for Prostate Cancer Through Genomics
Roychowdhury, S., & Chinnaiyan, A. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3662 · Cited by 90
Self-citationModification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG
Pettersson, A., Lis, R. T., Meisner, A., Flavin, R., Stack, E. C., Fiorentino, M., Finn, S. P., Graff, R. E., Penney, K. L., Rider, J. R., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt332 · Cited by 89
Emergence of the Noncoding Cancer Genome: A Target of Genetic and Epigenetic Alterations
Zhou, S., Treloar, A. E., & Lupien, M. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0745 · Cited by 100
The Hippo Pathway in Prostate Cancer
Salem, O., & Hansen, C. G. (2019) · Cells · doi:10.3390/cells8040370 · Cited by 102
“C chemokine receptor type 2 CYR61 Cysteine-rich angiogenic factor DHT Dihydrotestosterone DNMT3a DNA methyltransferase 3 ECM Extracellular matrix EMT Epithelial–mesenchymal transition ER Estrogen receptor ERG ETS-regulated gene ETS E26 transformation-specific transcription factors ETV1/4/5 E26 transformation-specific…”
BackgroundInfluentialβ4 Integrin signaling induces expansion of prostate tumor progenitors
Yoshioka, T., Otero, J., Chen, Y., Kim, Y.-M., Koutcher, J. A., Satagopan, J., Reuter, V., Carver, B., de Stanchina, E., Enomoto, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60720 · Cited by 87
Long Noncoding RNAs as Putative Biomarkers for Prostate Cancer Detection
Lee, B., Mazar, J., Aftab, M. N., Qi, F., Shelley, J. P., Li, J., Govindarajan, S. S., Valerio, F., Rivera, I., Thurn, T., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.06.009 · Cited by 92
Distinct genomic aberrations associated with ERG rearranged prostate cancer
Demichelis, F., Setlur, S. R., Beroukhim, R., Perner, S., Korbel, J. O., LaFargue, C. J., Pflueger, D., Pina, C., Hofer, M. D., Sboner, A., et al. (2009) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20647 · Cited by 91
“VC 2009 Wiley-Liss, Inc. recurrent fusions of the androgen-regulated gene TMPRSS2 (Transmembrane protease, serine 2) and the transcription factors ERG and ETV1 (Tomlins et al., 2005), subsequent studies showed additional fusions involving the ETS genes and various 50 partners (Tomlins et al., 2006, 2007; Helgeson et a…”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109–0602, USA.
- Corresponding author
- Chinnaiyan, Arul M.
- ORCID
- Venue
- Science
- Published
- 2005-10-28
- Volume
- 310
- Issue
- 5748
- Pages
- 644-648
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2121158863
- Cited by
- 3,846
- References
- 32
- Citations by year
- 2026: 77 · 2025: 99 · 2024: 82 · 2023: 108 · 2022: 137 · 2021: 163 · 2020: 187 · 2019: 172 · 2018: 178 · 2017: 218 · 2016: 209 · 2015: 244 · 2014: 271 · 2013: 309 · 2012: 279
- FWCI
- 114.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG021404, R01 AG 21404)
- National Cancer Institute (UO1 CA111275-01, P50-CA-69568, U01CA111275, R01CA097063, R01 CA97063, 5P30 CA 46592, P50CA069568, P30CA046592)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- TMPRSS2-ERG fusion, prostate cancer, ETS transcription factors, chromosomal rearrangements, gene fusion, molecular diagnosis
- MeSH terms
- Transcriptional Regulator ERG, Androgens, DNA-Binding Proteins, Humans, Male, Membrane Proteins, Molecular Sequence Data, Neoplasm Proteins, Prostatic Neoplasms, Serine Endopeptidases, Transcription Factors, Translocation, Genetic, Gene Rearrangement, Oncogene Proteins, Fusion, Trans-Activators, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, In Situ Hybridization, Fluorescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.